Radiopharmaceutical Therapy for Advanced Prostate Cancer: Advancing Precision Oncology Through Theranostics

The treatment landscape for advanced prostate cancer continues to evolve rapidly, with radiopharmaceutical therapy emerging as a key component of precision oncology. Leveraging a theranostic approach that integrates molecular imaging and targeted radionuclide therapy, radiopharmaceuticals enable clinicians to identify and treat prostate cancer at the cellular level while minimizing exposure to surrounding healthy tissues.

For patients with metastatic castration-resistant prostate cancer (mCRPC), these therapies offer an important treatment modality that complements systemic therapy and may improve outcomes in appropriately selected patients.

Understanding Radiopharmaceuticals

Radiopharmaceuticals combine a targeting molecule with a radioactive isotope to selectively bind to cancer cells and deliver radiation directly to sites of disease. Unlike external beam radiation therapy, which targets a defined anatomical area, radiopharmaceuticals circulate systemically and can identify and treat metastatic lesions throughout the body.

In prostate cancer, many radiopharmaceutical strategies target prostate-specific membrane antigen (PSMA), a transmembrane protein that is highly expressed on the surface of prostate cancer cells, particularly in advanced and metastatic disease.

This targeted mechanism allows clinicians to both visualize disease burden and deliver therapeutic radiation using related compounds directed at the same molecular target.

The Theranostic Paradigm: From Diagnosis to Treatment

The integration of diagnostic and therapeutic radiopharmaceuticals has transformed the management of advanced prostate cancer.

PSMA PET Imaging

Radiopharmaceutical imaging agents such as Pylarify® (piflufolastat F 18) and Illuccix® (gallium Ga 68 gozetotide) bind to PSMA-expressing cells and allow highly sensitive detection of disease using PET/CT imaging.

Compared with conventional imaging modalities, PSMA PET has demonstrated superior sensitivity for identifying metastatic and recurrent disease, helping clinicians more accurately stage patients, assess disease burden, and guide treatment decisions.

At Maryland Oncology Hematology, PSMA PET imaging plays an important role in identifying patients who may benefit from PSMA-targeted therapies and ensuring appropriate patient selection.

PSMA-Targeted Radioligand Therapy

Building on the same targeting principle, therapeutic radiopharmaceuticals deliver cytotoxic radiation directly to PSMA-positive tumor cells.

Pluvicto® (lutetium Lu 177 vipivotide tetraxetan) is a PSMA-directed radioligand therapy approved for eligible patients with PSMA-positive metastatic castration-resistant prostate cancer. Following intravenous administration, the radioligand binds to PSMA-expressing cells and delivers beta-particle radiation directly to tumor sites throughout the body, including both osseous and soft-tissue metastases.

This targeted delivery mechanism allows treatment of disseminated disease while limiting radiation exposure to non-target tissues.

Patient Selection and Multidisciplinary Evaluation

Appropriate patient selection remains critical to optimizing outcomes with radiopharmaceutical therapy.

Patients considered for PSMA-targeted radioligand therapy typically undergo comprehensive evaluation that includes:

PSMA PET imaging to confirm target expression
Assessment of disease burden and distribution
Review of prior systemic therapies
Evaluation of performance status and organ function
Multidisciplinary review of available treatment options

At Maryland Oncology Hematology, treatment recommendations are developed through close collaboration among medical oncologists, radiation oncologists, nuclear medicine specialists, advanced practice providers, and supportive care teams. This multidisciplinary approach ensures radiopharmaceutical therapy is thoughtfully integrated into each patient’s overall treatment strategy.

“Radiopharmaceutical therapy has transformed the treatment of advanced prostate cancer. Treatments like Pluvicto® deliver targeted radiation to cancer cells throughout the body, offering new hope for eligible patients. At Maryland Oncology Hematology, both myself and Dr. Samir Kanani see patients at our White Oak and Shady Grove locations, with treatments provided at our Silver Spring center. Together with our multidisciplinary team, we are committed to delivering personalized, leading-edge cancer care!”
— Dr. Luqman Dad, Radiation Service Line Chief, Maryland Oncology Hematology

Maryland Oncology Hematology’s Radiopharmaceutical Program

Maryland Oncology Hematology provides patients and referring physicians access to advanced molecular imaging, PSMA-targeted radioligand therapy, and comprehensive multidisciplinary cancer care.

Our experienced team combines expertise in medical oncology, radiation oncology, and nuclear medicine to develop individualized treatment plans for patients with advanced prostate cancer. Through access to innovative therapies such as Pluvicto®, advanced radiation technologies, and evidence-based systemic treatments, we are able to offer a coordinated approach to managing complex cases across the continuum of care.

Looking Ahead

Radiopharmaceutical therapy represents one of the most significant advances in prostate cancer treatment in recent years. As the clinical applications of theranostics continue to expand, PSMA-targeted imaging and radioligand therapy are expected to play an increasingly important role in the management of advanced prostate cancer.

For referring physicians and patients alike, these innovations offer new opportunities to personalize treatment, improve disease control, and expand access to cutting-edge cancer care.

To learn more about Maryland Oncology Hematology’s Radiopharmaceutical Therapy Program or to refer a patient, contact our team today.

White Oak Cancer Center Radiation Oncology / Silver Spring: 240-471-3800

Aquilino Cancer Center Radiation Oncology / Rockville: 301-309-6765